• FDA Approves IND of AmnioFix americanpharmaceuticacreview
    October 18, 2017
    MiMedx Group announced the company has been notified by the Food and Drug Administration (FDA) that its Investigational New Drug (IND) Phase 2B clinical study for osteoarthritis of the knee may proceed.
PharmaSources Customer Service